Samsung Biologics has officially begun construction of its Plant 4 in Incheon, South Korea. Dubbed the “Super Plant,” the new, multi-story 2.5 million sq. ft. construction will be the world’s largest biopharmaceutical manufacturing facility of its kind boasting 256,000 liters total manufacturing capacity. Upon completion of Plant 4, Samsung Biologics is expected to be accountable for a third of the total global bio-CMO manufacturing capacity, offering a combined sum of 620,000 liters from a single site. Plant 4 also features a modular design that will allow flexibility for certain parts of the plant to begin manufacturing activities by the end of 2022, with the goal to commence full operations in 2023.